Open-Label, Multi-country and Multi-Center Study to Asses the Clinical Efficacy and impact on QoL of the Fully Human Anti-TNF-alfa Monoclonal Antibody Adalimumab (Humira) when Added to Inadequate Standard Anti-Rheumatic Therapy in patients with Active Rheumatoid Arthritis in a period of 6 months treatment.

Study Identifier
W10-045
CT.gov Identifier
W10-045
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Rheumatoid Arthritis
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    N/A
    Inclusion and Exclusion Criteria

    Protocol Summary

    To demonstrate the efficacy and safety of adalimumab when added to preexisting inadequate standard anti-rheumatic therapy in patients with moderate to severely active rheumatoid arthritis

    Study Locations

    No locations found.